Felix Lansing, PhD

Chief Technology Officer @ Seamless Therapeutics

About

Dr. Felix Lansing, a visionary scientist and entrepreneur, co-founded SeamlessTx, a biotech start-up focused on advancing gene therapies for hereditary diseases using Programmable-Recombinases.After excelling with a Bachelor's in Molecular Biology, he pursued a Master's in Regenerative Biology and Medicine, achieving outstanding results. In 2017, Dr. Lansing embarked on a pioneering PhD thesis at TU Dresden, developing Programmable-Recombinases for Hemophilia A treatment. The research yielded groundbreaking results, earning him the highest distinction and leading to several patent applications and publications.His exceptional contributions have been recognized with prestigious awards, including the 'German Study Award' of the Körber Foundation and the 'Excellence Award' by the city of Dresden, among others.Moreover, Dr. Lansing played a pivotal role in securing the seed funding of 25 million USD for SeamlessTx and was instrumental in establishing a pharmaceutical partnership with Eli Lilly, representing a total potential deal volume of 1.12 billion USD - a testament to the transformative commercial and therapeutic potential of SeamlessTx's recombinase platform.As Chief Technology Officer at SeamlessTx, Dr. Lansing leads a dedicated team revolutionizing gene editing by providing effective and accessible gene therapies for hereditary diseases and other severe disorders based on recombinases.

Country

Germany

City

Greater Dresden Area

Industry

Biotechnology

Skill

C Level Management, Communication, Teamwork, Cross-functional Team Leadership, Leadership, Project Planning, Molecular Biology, Molecular Cloning, Cell Biology, Molecular Genetics, Stem Cells, Immunohistochemistry, R Studio, Western Blotting, qRT-PCR, Molecular Imaging, FACS, Cell Culture, Statistics

Experience

Chief Technology Officer

Seamless Therapeutics

2023-1 - Present · 3 yrs 9 mos

Dresden

Assumed the CTO role following successful investment, taking ownership of the company's technology vision and strategic narrative. Responsible for shaping and communicating the technological direction of the company to investors, board members, and the broader scientific community — including representation at international conferences and industry events. Prepares and presents board-level materials, translating complex technical progress into clear strategic insights for stakeholders. Heads a multidisciplinary team across internal research and external collaborations, taking projects from the conceptualization of recombinase-based therapeutics through protein engineering and into proof-of-concept studies in human cells and other model systems.

Co-Founder

Seamless Therapeutics

2022-4 - Present · 4 yrs 6 mos

Board Member

Seamless Therapeutics

2022-6 - 2025-4 · 2 yrs 11 mos

Served as a Board Member at the early-stage of Seamless Therapeutics, providing strategic oversight and independent scientific counsel to the executive team during a critical phase of the company's development. Contributed to foundational decisions around research strategy, pipeline prioritization, and scientific positioning, helping to align the company's technical direction with its long-term ambitions. Actively participated in board-level discussions on key milestones including fundraising, partnership development, and the translation of early-stage science into a compelling and credible therapeutic narrative.

Lead Scientist for Science & Technology Strategy

Seamless Therapeutics

2022-1 - 2022-12 · 1 yr

Led the scientific and technical narrative for the company's spinout from university, shaping the pitch strategy and serving as the primary scientific voice for investors engagements. Took ownership of the scientific spinout journey, bridging the gap between academic research and commercial reality through clear, compelling storytelling.

Scientist

Technische Universität Dresden

2021-5 - 2022-12 · 1 yr 8 mos

PhD Student

Technische Universität Dresden

2017-4 - 2021-4 · 4 yrs 1 mo

Greater Dresden Area

PhD Student in the Dresden International Graduate School for Biomedicine and Bioengineering at UCC, Medical Systems Biology, Medical Faculty, TU Dresden Project: Directed evolution of site-specific recombinases for precise genome editing and rearrangement

Research Scholar

Cincinnati Children's

2019-10 - 2020-3 · 6 mos

Cincinnati

During my stay in Cincinnati with Takanori Takebe I have learned to differentiate human induced pluripotent stem cells to Liverbuds and Human liver organoids (HLO).

Master Thesis in the group of Prof. Dr. Frank Buchholz (Medical Systems Biology)

UCC, Medical Systems Biology Medical Faculty, TU Dresden

2016-3 - 2016-10 · 8 mos

Dresden

Directed evolution of a site specific recombinase to target factor VIII gene inversion for Hemophilia A treatment

Intern in the group of Prof. Dr. Marius Ader (Cell Replacement in the Mammalian Retina)

Center for Regenerative Therapies Dresden (CRTD)

2015-10 - 2016-3 · 6 mos

Dresden

Identification of specific cell-surface markers for cone sorting

Intern in the group of Dr. Christian Bökel (Stem Cell Niches in Drosophila)

Center for Regenerative Therapies Dresden (CRTD)

2015-4 - 2015-9 · 6 mos

The Drosophila Melanogaster Testis Stem Cell Niche - A novel role of the Hippo pathway?

Intern in the group of Prof. Dr. Triantafyllos Chavakis (Department of Clinical Pathobiochemistry)

Medizinisch-Theoretisches Zentrum (MTZ) Dresden

2014-10 - 2015-3 · 6 mos

Dresden

Direct effects of NGF on TLR4 signaling in microglia

Intern in the group of Prof. Dr. Thierry Frebourg (Genetics of Cancer and Neurogenetics)

INSERM Unit U1079 - Genetics of Cancer and Neurogenetics

2013-11 - 2014-2 · 4 mos

Rouen Area, France

Analysis of the effect of single nucleotide variants in exon 7 of MLH1 on RNA splicing by using minigene assays

Education

Technische Universität Dresden

Gene/Genetic Therapy

2017-4 - 2022-1 · 4 yrs 10 mos

Technische Universität Dresden

Regenerative Biology and Medicine

2014 - 2016 · 2 yrs

Bielefeld University

Molecular Biology

2011 - 2014 · 3 yrs